EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gut‐Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3 /c‐Myc Signaling Axis

Yong Sun iD, Huayue Wu, Yutong Zhou, Pengsheng Yin, Long Wu, Haiyang Li, Shi Zuo, Zhe Yang, Kun Cao

The FASEB Journal · 31.07.2026 · 40 (14)

DOI: 10.1096/fj.202504713r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 13.07.2026. Verfasst von Yong Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China. Hauptthemen laut MEDLINE: Butyric Acid, Histone Deacetylases, Liver Cirrhosis, Glycolysis. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Youth-Guided Basic Research Program of the Guizhou Provincial Department of Science and Technology, National Natural Science Foundation of China, Guizhou Provincial Key Laboratory for Digestive System Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis remains a major global health challenge, driving interest in bioactive metabolites from natural sources as potential therapies. Sodium butyrate (NaB), a gut microbiota–derived short‐chain fatty acid with notable anti‐fibrotic activity, shows promise, although its mechanisms remain unclear. This study aims to explore the molecular mechanisms through which NaB attenuates liver fibrosis. This study integrates bioinformatics and network pharmacology to predict the molecular targets through which NaB exerts its anti‐fibrotic effects. Candidate targets were validated through molecular docking, histopathology, CETSA, and SPR. The inferred mechanisms were further validated in vitro (LX‐2 cells) and in vivo (CCl 4 ‐induced mice) using Western blot, IF Co‐IP, RT‐qPCR, ELISA, and histopathological staining. HDAC3 was identified as a key driver of liver fibrosis. As a natural HDAC3 inhibitor, NaB markedly attenuated CCl 4 ‐induced hepatic injury and fibrosis, accompanied by reduced expression of HDAC3, c‐Myc, glycolytic enzymes (HK2, PFKFB3, and PKM2), and fibrotic markers (α‐SMA and type I collagen) in fibrotic liver tissues and LX‐2 cells. Mechanistically, NaB exerts its anti‐fibrotic effects by inhibiting HDAC3 expression and deacetylase activity, promoting c‐Myc acetylation and downregulating its expression, thereby suppressing glycolytic metabolic reprogramming in hepatic stellate cells. These findings indicate that NaB attenuates liver fibrosis by inhibiting HDAC3/c‐Myc–mediated metabolic reprogramming, revealing a gut‐derived anti‐fibrotic mechanism and potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Butyric AcidHistone DeacetylasesLiver CirrhosisGlycolysisSignal TransductionProto-Oncogene Proteins c-mycAnimalsHistone Deacetylase 3MiceHumansMaleMice, Inbred C57BLHepatic Stellate CellsCell Line

Stichwörter der Autor:innen

glycolysishepatic stellate cellshistone deacetylasesliver fibrosissodium butyrate

Substanzen

Butyric AcidHistone DeacetylasesHistone Deacetylase 3Proto-Oncogene Proteins c-myc

Autor:innen und Institutionen

  • School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
  • Department of Hepatobiliary Surgery, Guizhou Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guiyang, Guizhou, China.
  • Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
  • The Provincial Key Laboratory of Digestive System Diseases of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou, China.
  • School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.

ORCID-Profile: Yong Sun

Förderung

  • Youth-Guided Basic Research Program of the Guizhou Provincial Department of Science and Technology
  • National Natural Science Foundation of China
  • Guizhou Provincial Key Laboratory for Digestive System Diseases
  • Basic Research Program (General Project) of the Guizhou Provincial Department of Science and Technology
  • Technology Foundation of Guizhou Health Committee
  • Project of Key Laboratory of Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases and Bioinformatics Research, Guizhou Medical University

Zitieren

APA

Sun, Y., Wu, H., Zhou, Y., Yin, P., Wu, L., Li, H., Zuo, S., Yang, Z., & Cao, K. (2026). Gut‐Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3 /c‐Myc Signaling Axis. The FASEB Journal, 40(14). https://doi.org/10.1096/fj.202504713r

Vancouver

Sun Y, Wu H, Zhou Y, Yin P, Wu L, Li H, et al. Gut‐Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3 /c‐Myc Signaling Axis. The FASEB Journal. 2026;40(14). doi:10.1096/fj.202504713r

BibTeX
@article{Sun2026,
  author = {Sun, Yong and Wu, Huayue and Zhou, Yutong and Yin, Pengsheng and Wu, Long and Li, Haiyang and Zuo, Shi and Yang, Zhe and Cao, Kun},
  title = {Gut‐Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3 /c‐Myc Signaling Axis},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {14},
  doi = {10.1096/fj.202504713r}
}
Kostenlos starten →